Portfolio company
March Biosciences
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
4 investors
Sectors
About
This clinical-stage company develops CAR-T cell therapies for patients with challenging hematological cancers, including T-cell lymphoma.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
CARGO Therapeutics
This biotechnology company develops engineered cell therapies to treat cancer patients with relapsed or resistant lymphoma.
curocell
This company develops chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory blood cancers such as diffuse large B-cell lymphoma.
Caribou Biosciences
This biopharmaceutical company develops genome-edited allogeneic cell therapies to treat patients with hematologic malignancies and other human diseases.
Lyell Immunopharma
This biopharmaceutical company develops chimeric antigen receptor T-cell therapies to treat patients with hematologic malignancies and solid tumours.
Verismo Therapeutics
This company develops chimeric antigen receptor therapies for patients with solid tumours and B-cell lymphomas.
PanCancerT
This biotech company develops T-cell receptor therapies for patients with solid tumours, focusing on targets like triple-negative breast cancer and melanoma.
T-CURX
This biotech company develops non-viral CAR-T cell therapies to treat patients with leukaemia, lymphoma and solid tumours.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.